Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
S 0.105 −32.3% OMI 0.310 −1.6% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.260 −7.1% CAMB 0.950 −5.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.00 −2.9% SGQ 0.400 +33.3% AMCO 0.225 −10.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.395 −1.2% LIB 0.780 −14.3% SMY 0.290 +23.4% S 0.105 −32.3% OMI 0.310 −1.6% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.260 −7.1% CAMB 0.950 −5.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.00 −2.9% SGQ 0.400 +33.3% AMCO 0.225 −10.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.395 −1.2% LIB 0.780 −14.3% SMY 0.290 +23.4%
Production / Operations

Red Light Holland's FDA-Compliant, DEA-Registered Partner Irvine Labs Receives Second, Larger 5kg Psilocybin Shipment via USA Controlled Substances Import Permit

By The Northwire Desk — AI Analysis Nov 19, 2025 · 07:46 TRIP · 0.03 Red Light Holland Corp.
TRIP · Price

Executive Summary

  • Red Light Holland shipped a second, larger batch of natural psilocybin (5 kg) from its Netherlands facility to FDA‑compliant, DEA‑registered partner Irvine Labs in California.
  • The shipment demonstrates successful scaling of the supply chain and supports expanded research on dehydration, packaging, and medical‑grade manufacturing processes.
  • The company issued 3,250,719 common shares at a deemed price of $0.035 per share to settle debt with arm’s‑length creditors.

Key Details

  • Shipment Size: 5 kg of natural psilocybin – second shipment, larger than the initial July 2025 delivery.
  • Regulatory Approvals: Export approved under U.S. Controlled Substances import permit; processed using Irvine Labs’ existing 2025 DEA quota allocation.
  • Purpose: Enables expanded R&D activities, including validation of proprietary dehydration and packaging processes to extend shelf life while maintaining product integrity for potential therapeutic applications.
  • Partnership Progress: Confirms viability of the Red Light Holland–Irvine Labs collaboration and strengthens supply‑chain reliability for future medical‑grade product development.
  • CEO Quote (Todd Shapiro): Highlights the significance of scaling R&D operations and the strength of the partnership.
  • President Quote (Shaun Land, Irvine Labs): Emphasizes the ability to conduct more comprehensive testing and advance toward standardized therapeutic products.
  • Debt Settlement: Issuance of 3,250,719 common shares at $0.035 per share to arm’s‑length creditors as part of a debt settlement arrangement.

Notable Quotes

“This second and larger shipment represents significant progress in scaling our R&D operations,” – Todd Shapiro, CEO & Director, Red Light Holland.

“This larger shipment allows us to conduct more comprehensive testing of our preservation processes… we’re excited to advance toward standardized products for emerging therapeutic markets.” – Shaun Land, President, Irvine Labs.

Read the original news release →

More from Red Light Holland Corp.

Jun 18, 2026 · 09:02

Early-stage preclinical milestone adds to pipeline, but stock has already priced in a +200% run; execution risk remains high.

Other Jun 08, 2026 · 07:31

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Other Jun 04, 2026 · 07:32

Red Light Holland Secures UCSF Supply Deal for PEX010, But Clinical Progress Remains Incremental Amid Dilution Concerns

Other May 25, 2026 · 08:40

Red Light Holland Expands Filament Health Psychedelic Supply Footprint in New Zealand

Other May 14, 2026 · 08:31

Red Light Holland expands its clinical psilocybin network, but mounting share dilution and a transition to pharma leave investors waiting for a clear commercial catalyst.

Production / Operations May 13, 2026 · 09:13

Red Light Holland Consolidates Psychedelic Platform Post-Acquisition Amidst Management Transition

Financings